home / stock / nrbo / nrbo news


NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 06/15/21

Stock Information

Company Name: NeuroBo Pharmaceuticals Inc.
Stock Symbol: NRBO
Market: NASDAQ
Website: neurobopharma.com

Menu

NRBO NRBO Quote NRBO Short NRBO News NRBO Articles NRBO Message Board
Get NRBO Alerts

News, Short Squeeze, Breakout and More Instantly...

NRBO - Clearside Biomedical, Eloxx Pharmaceuticals leads healthcare gainers; PDS Biotechnology, Sage Therapeutics among major losers

Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, Neu...

NRBO - Petco Health and Wellness, Vroom among premarket losers' pack

Document Security Systems DSS -41% after secures $43.5M capital via equity raise.PDS Biotechnology PDSB -16% on proposing stock offering.Sage Therapeutics SAGE -12% after disappointing zuranolone secondary data in depression study.Vascular Biogenics VBLT -12...

NRBO - NeuroBo on track to post a record gain after announcing a special meeting

JuSun/iStock via Getty Images NeuroBo Pharmaceuticals ([[NRBO]] +31.8%) is on course to witness its biggest one-day gain in more than a year today. Last week, the company announced an upcoming Special Meeting scheduled to seek stockholder approval for the issuance of common stock. The of...

NRBO - NeuroBo Pharmaceuticals EPS beats by $0.01

NeuroBo Pharmaceuticals (NRBO): Q1 GAAP EPS of -$0.15 beats by $0.01.Cash and Cash Equivalents were $13MPress Release For further details see: NeuroBo Pharmaceuticals EPS beats by $0.01

NRBO - NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results

NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal di...

NRBO - Shares of NeuroBo Pharmaceuticals Inc. (NRBO) Fall Below Previous 52-Week Low

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.33. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is en...

NRBO - NeuroBo Pharmaceuticals Inc. Looks to Continue to Trade Below its Annual-Low Share Price Today

Shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded today at $3.20, breaking its 52-week low. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. Potential upside of 65.6% exists for NeuroBo Pharmaceuticals...

NRBO - Purple Biotech, NeuroBo Pharmaceuticals leads healthcare gainers; Syndax Pharmaceuticals, Zai Lab among major losers

Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...

NRBO - Shares of NeuroBo Pharmaceuticals Inc. (NRBO) Have Fallen Below Previous 52-Week Low

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.17. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc. share prices have moved between a 52-week high...

NRBO - NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 PR Newswire BOSTON , A...

Previous 10 Next 10